Facial erythema after the treatment of dupilumab in SLE patient

Facial erythema after the treatment of dupilumab in SLE patient

Abstract Background Dupilumab is a receptor antagonist binding to the alpha subunit of the interleukin-4 receptor. Through binding to it, dupilumab inhibits signaling of both IL-4 and IL-13, the representative Th2 biomarkers. Recently, in addition to the treatment effects for atopic dermatitis (AD),...

Full description

Bibliographic Details
Main Authors: Dong Hyek Jang, Jae In Lee, Joo Yoon Bae, Hye Jung Jung, Mi Yeon Park, Jiyoung Ahn
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Atopic dermatitis
Dupilumab
Facial erythema
SLE
Online Access:http://link.springer.com/article/10.1186/s13223-020-00458-6

Internet

http://link.springer.com/article/10.1186/s13223-020-00458-6

Similar Items